CE / CME
In this certified on-demand webcast, experts discuss the management of CLL/SLL therapy from frontline treatment to relapsed/refractory disease based on evidence from recent clinical trials and current NCCN guidelines as well as future directions to personalize and optimize patient care.
Physicians: maximum of 1.50 AMA PRA Category 1 Credits
Registered Nurses: 1.50 Nursing contact hour
Physician Assistants: maximum of 1.50 hours of AAPA Category 1 CME credits
Pharmacists: 1.50 contact hours (0.15 CEUs)
ABIM MOC: maximum of 1.50 Medical Knowledge MOC points
Released: June 19, 2025
Expiration: December 18, 2025
Share
Provided by the National Comprehensive Cancer Network (NCCN) in collaboration with Clinical Care Options, LLC
Supported by an independent medical education grant from AbbVie. Supported by educational grants from Bristol Myers Squibb and Lilly.
AbbVie Inc.
Bristol Myers Squibb
Lilly
Clinical Care Options, LLC
This activity is intended for oncologists, PAs, nurses, pharmacists, and other healthcare professionals who care for patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
This activity aims to improve learners' knowledge, competence, and confidence to integrate new and emerging therapies into practice to improve clinical outcomes in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma.
Upon completion of this activity, participants should be able to:
Select first-line therapy for treatment-naive CLL/SLL, considering the available evidence, expert and guideline recommendations, toxicity profiles, prognostic variables, comorbidities, duration of treatment (continuous vs. fixed duration), and patient preference
Evaluate intraclass differences in selectivity, binding, efficacy, and adverse event profiles of targeted agents used to treat CLL/SLL
Plan individualized treatment approaches for relapsed/refractory CLL/SLL based on optimal sequencing strategies recommended in the NCCN Guidelines (eg, assessment of response/intolerance to first-line therapy, testing for resistant mutations, and patient eligibility for treatment)
Identify patients with CLL/SLL who may be eligible for allogeneic HCT or enrollment in a clinical trial
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers, and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Definitions
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
Faculty Disclaimers
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
Primary AuthorDanielle M. Brander, MD: consultant/advisor: AbbVie, BeiGene, Bristol Myers Squibb, Pharmacyclics; researcher (paid to institution): AbbVie, ArQule/Merck, AstraZeneca/Acerta, BeiGene, Bristol Myers Squibb, Carna Biosciences, Catapult, DTRM, Genentech, NeWave, Nurix, Pharmacyclics, TG Therapeutics; other financial or material support: AbbVie, Pharmacyclics.
Brad Kahl, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, GlaxoSmithKline, Incyte, Lilly, Merck, Pfizer, Roche.
Sameer A. Parikh, MBBS: researcher (paid to institution): AstraZeneca, Genentech, Janssen, Merck; consultant/advisor/speaker (paid to institution): AbbVie, Amgen, AstraZeneca, BeiGene, Genentech, Janssen, Kite, Merck, MingSight, Novalgen Limited, Pharmacyclics, TG Therapeutics.
NCCN and CCO Staff Disclosures
None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients
Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 19, 2025, through December 18, 2025:
Login or Sign Up for an account by clicking at the top of this page.
Read the target audience, learning objectives, and faculty disclosures.
View and study the content in its entirety.
Submit answers to the posttest questions and evaluation questions online.
You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.
This program has been made available online.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Joint Accreditation Statement
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
NCCN designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
NCCN designates this educational activity for a maximum of 1.5 contact hours. This activity offers 1.5 pharmacotherapeutic contact hours for nurses.
Continuing Pharmacy Education
NCCN designates this knowledge-based continuing education activity for 1.5 contact hours (0.15 CEUs) of continuing education credit. UAN: JA4008196-0000-25-097-H01-P
Type of Activity: Knowledge
Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.
Physician Associate Continuing Medical Education
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 18, 2025. PAs should only claim credit commensurate with the extent of their participation.
American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregated participant data will be shared with the commercial supporters of this activity.
For ABIM MOC points, your information will be shared with the ABIM through NCCN's Joint Accreditation Program and Activity Reporting System (JA-PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.
By sharing your Diplomate Board ID # and DOB, you are giving NCCN permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).